Date: 2016-06-02
Type of information: Grant
Company: Miragen Therapeutics (USA - CO)
Investors: ALS association (USA -DC)
Amount: up to $424,725
Funding type: grant
Planned used: The Translational Research Advancing Therapy for ALS (TREAT ALS™) grant will be used to advance the development of MRG-107, a synthetic microRNA antagonist (LNA antimiR®) of microRNA-155 that is effective in pre-clinical models of amyotrophic lateral sclerosis.
Others: • On June 2, 2016, miRagen Therapeutics and the ALS Association announced that miRagen has received the first installment of a Translational Research Advancing Therapy for ALS (TREAT ALS™) grant. This milestone-driven grant of up to $424,725 will be used to advance the development of MRG-107, a synthetic microRNA antagonist (LNA antimiR®) of microRNA-155 that is effective in pre-clinical models of amyotrophic lateral sclerosis (ALS).
Therapeutic area: Neurodegenerative diseases
